drugset / Trial / NCT00681356

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT00681356

Phase 3 Completed 214 enrolled Anesiva, Inc.
RandomizedParallel-groupDouble-blindSupportive care

Summary

Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement

Timeline

Start
2007-09
Primary completion
2008-09
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 5 mg Other
Subject Capsaicin Small molecule 15 mg Other

Indications

No indication recorded.